Advertisement
Research Article

Limited TCF7L2 Expression in MS Lesions

  • Alexander Lürbke,

    Affiliation: Institute of Neuropathology, University Hospital Münster, Münster, Germany

    X
  • Karin Hagemeier,

    Affiliation: Institute of Neuropathology, University Hospital Münster, Münster, Germany

    X
  • Qiao-Ling Cui,

    Affiliation: Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Canada

    X
  • Imke Metz,

    Affiliation: Department of Neuropathology, University Medical Center, Göttingen, Germany

    X
  • Wolfgang Brück,

    Affiliation: Department of Neuropathology, University Medical Center, Göttingen, Germany

    X
  • Jack Antel,

    Affiliation: Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Canada

    X
  • Tanja Kuhlmann mail

    tanja.kuhlmann@ukmuenster.de

    Affiliation: Institute of Neuropathology, University Hospital Münster, Münster, Germany

    X
  • Published: August 20, 2013
  • DOI: 10.1371/journal.pone.0072822

Abstract

Multiple sclerosis is the most frequent demyelinating disease in the human CNS characterized by inflammation, demyelination, relative axonal loss and gliosis. Remyelination occurs, but is frequently absent or restricted to a small remyelinated rim at the lesion border. Impaired differentiation of oligodendroglial precursor cells is one factor contributing to limited remyelination, especially in chronic MS. TCF7L2 is an oligodendroglial transcription factor regulating myelin gene expression during developmental myelination as well as remyelination. TCF7L2 binds to co-effectors such as β-catenin or histone deacetylases and thereby activates or inhibits the transcription of downstream genes involved in oligodendroglial differentiation. To determine whether TCF7L2 can be used as a marker for differentiating or myelinating oligodendrocytes, we analyzed the expression patterns of TCF7L2 during myelination and remyelination in human and murine CNS tissue samples. Here, we demonstrate that marked expression of TCF7L2 in oligodendrocytes is restricted to a well defined time period during developmental myelination in human and mouse CNS tissue samples. In demyelinating diseases, such as multiple sclerosis, TCF7L2 is reexpressed in oligodendrocytes in a subset of MS patients, but is also present in tissue samples from patients with non-demyelinating, inflammatory diseases. Furthermore, TCF7L2 expression was also detected in astrocytes. HDAC2, a potential binding partner of TCF7L2 that promotes oligodendroglial differentiation and myelination, is expressed in the majority of oligodendrocytes in controls and MS tissue samples. In summary, our data demonstrate that the expression of TCF7L2 in oligodendrocytes is limited to a certain differentiation stage; however the expression of TCF7L2 is neither restricted to the oligodendroglial lineage nor to (re-)myelinating conditions.

Introduction

In Multiple sclerosis (MS) loss of axons is a prominent feature that correlates with neurological impairment [14]. In vivo imaging findings support the importance of axonal loss for persistent disability [5,6]. Demyelination contributes to axonal damage by increased vulnerability to immune mediated injury and lack of trophic support from myelin sheaths [7,8]. Furthermore, lack of remyelination is associated with increased axonal damage and loss in demyelinating animal models and MS lesions [911]. Promotion of remyelination appears to be an attractive neuroprotective strategy in demyelinating diseases. However, although remyelination is a frequent event in early MS lesions, it is limited in chronic lesion stages [12,13]. Only about 20% of chronic MS lesions show extensive remyelination of more than 50% of the lesion area [14]. Limited remyelination despite the presence of OPCs in the majority of chronic MS lesions suggests that a differentiation block of oligodendrocytes contributes to remyelination failure [1517].

Differentiation and myelination of oligodendrocytes is regulated by a broad range of transcriptional (e.g. Olig1, Olig2, Nkx2.2, Sox10) and postranscriptional factors (e.g. microRNAs, histone modifications). TCF7L2 is a transcriptional factor that has been found to be transiently expressed in oligodendrocytes during myelination [18]. Mice lacking TCF7L2 have OPCs but fail to generate mature oligodendrocytes. TCF7L2 is an effector of the wnt/β-catenin-pathway and the expression of members of the wnt/β-catenin-pathway and TCF7L2 has been observed in MS lesions. Enforced constitutive expression of β-catenin inhibited myelination and differentiation of oligodendrocytes leading to the suggestion that a disturbed wnt/β-catenin-pathway may contribute to remyelination failure in chronic MS lesions [18,19]. Alternatively, TCF7L2 may bind to histone deacetylases and promotes differentiation of oligodendrocytes [19].

Here we demonstrate that during myelination in the human and mouse CNS TCF7L2 expression is limited to a defined differentiation stage of oligodendroglial lineage cells. In early MS lesions TCF7L2 expression is a relatively rare phenomenon and most prominent in periplaque white matter and remyelinating lesion areas whereas in chronic MS lesions TCF7L2 expression was completely absent. However, reexpression of TCF7L2 is neither limited to the oligodendroglial lineage nor to demyelinating lesions since we found a marked expression of this transcription factor in oligodendrocytes and astrocytes in inflammatory, non demyelinating diseases.

Materials and Methods

1. Tissue samples

Mouse tissue samples.

For developmental studies P10, P21, 8 weeks and 8 months old mice (n = 3 to 5 each) were sacrificed.

For the cuprizone experiments six- to eight-week-old male C57Bl/6 mice were purchased from Charles River (Sulzfeld, Germany). Animal handling and experiments were conducted according to the German animal protection laws and approved by the responsible governmental authority (Bezirksregierung Braunschweig; AZ G86.06 and LANUV Nordrhein-Westfalen (AZ 8.87-50.10.37.09.221)).

Cuprizone was prepared by adding 0.25% (w/w) cuprizone (Sigma) to powdered chow. Seven to eight week old C57Bl/6 mice were fed with cuprizone for up to 42 days. Mice were sacrificed 21, 42, 52 and 70 days (n = 3 each) after onset of cuprizone diet. Control animals (n = 3) received powdered chow without cuprizone. Mice were sacrificed under deep anaesthesia and perfused intracardially with ice-cold phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) perfusion. Brains (cuprizone experiments and developmental studies) and spinal cords (developmental studies) were removed and embedded in paraffin.

Four µm thick sections were stained with haematoxylin and eosin (HE) and Luxol-fast blue (LFB).

Human tissue samples.

We retrospectively investigated 53 brain tissue samples from 45 MS patients (33 biopsies/ 37 tissue blocks, 12 autopsies/ 18 tissue blocks), 8 tissue samples from 8 patients with other inflammatory non demyelinating diseases (all biopsies), 17 controls without neurological diseases (all biopsies) and 22 developmental tissue samples (30th gestation week to 48 months) (all autopsies). None of the study authors was involved in decision-making with respect to biopsy or autopsy. Patients’ details (sex, age, disease duration) are summarized in Table 1. Paraffin embedded MS autopsy cases were derived from a collection of multiple sclerosis autopsies collected at the Montreal Neurological Institute, McGill University, Montreal, Canada. The study was approved by the Ethics Committee of the University of Göttingen and Münster.

PatientsexAgeneuropathological diagnosisDisease duration prior to biopsy or autopsy/ disease course at follow up
1F38 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
2M44 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
3F26 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
4F52 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
5M57 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
6F45 yearsinflammatory demyelinating lesion, consistent with MS6 years/nk
7M71 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
8F60 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
9M65 yearsinflammatory demyelinating lesion, consistent with MS19 days/RRMS
10F37 yearsinflammatory demyelinating lesion, consistent with MS2.5 months/RRMS
11M32 yearsinflammatory demyelinating lesion, consistent with MS58 days/CIS
12F20 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
13F34 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
14F45 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
15F28 yearsinflammatory demyelinating lesion, consistent with MS13 days/CIS
16F40 yearsinflammatory demyelinating lesion, consistent with MSnk/CIS
17nk22 yearsinflammatory demyelinating lesion, consistent with MS9 days/CIS
18F37 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
19M28 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
20F22 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
21F31 yearsinflammatory demyelinating lesion, consistent with MS12 days/CIS
22F19 yearsinflammatory demyelinating lesion, consistent with MS17 days/CIS
23nknkinflammatory demyelinating lesion, consistent with MS9 days/CIS
24nknkinflammatory demyelinating lesion, consistent with MS7 days/RRMS
25F58 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
26F53 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
27F17 yearsinflammatory demyelinating lesion, consistent with MS4 days/CIS
28F54 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
29F42 yearsinflammatory demyelinating lesion, consistent with MS21 days/CIS
30M64 yearsinflammatory demyelinating lesion, consistent with MS23 days/CIS
31F54 yearsinflammatory demyelinating lesion, consistent with MSnk/nk
32F47 yearsinflammatory demyelinating lesion, consistent with MS36 days/CIS
33M31yearsinflammatory demyelinating lesion, consistent with MS6 days/CIS
34M63 yearsMS18 years/SPMS
35M69 yearsMS7 years/SPMS
36F74 yearsMSnk/nk
37M49 yearsMSnk/nk
38F35 yearsMSnk/nk
39F70 yearsMS7 years/PPMS
40F60 yearsMS14 years/PPMS
41F76 yearsMS20 years/nk
42M61 yearsMS32 years/SPMS
43M66 yearsMS34 years/SPMS
44M57 yearsMS29 years/SPMS
45nkNkMSnk/nk
46F58 yearsMS22 years/ probably PPMS
47M76 yearsencephalitisna/na
48F52 yearsgranulomatous encephalitisna/na
49F49 yearsToxoplasma encephalitisna/na
50F41yearsencephalitis/vasculitisna/na
51M64 yearschronic CNS inflammationna/na
52F77 yearsABRAna/na
53M73 yearsencephalitisna/na
54M61 yearsencephalitisna/na
55M39 yearscontrolna/na
56M29 yearscontrolna/na
57MNkcontrolna/na
58M32 yearscontrolna/na
59M30 yearscontrolna/na
60M40 yearscontrolna/na
61F39 yearscontrolna/na
62M25 yearscontrolna/na
63M64 yearscontrolna/na
64M72 yearscontrolna/na
65M62 yearscontrolna/na
66F61 yearscontrolna/na
67F24 yearscontrolna/na
68M50 yearscontrolna/na
69M63 yearscontrolna/na
70M72 yearscontrolna/na
71F47 yearscontrolna/na

Table 1. Patient details.

nk = not known; na = not applicable; CIS clinical isolated syndrome; RRMS = relapsing remitting MS; SPMS = secondary progressive MS; PPMS = primary progressive MS; ABRA = amyloid-beta related angiitis.

2. Classification of multiple sclerosis lesions

All lesions fulfilled the generally accepted criteria for the diagnosis of multiple sclerosis [2022]. Tissue samples from patients with early MS lesions (biopsies) showed the characteristics of active lesions; they were homogenously infiltrated by numerous macrophages. Early MS lesions were derived in general from patients with a short disease duration of days or few months (4 days to 2.5 months); however in one patient the disease duration was six years. In chronic MS tissue samples (autopsies) inflammation was limited to the lesion border (chronic active lesions) or was absent (chronic inactive lesions); these tissue samples were derived from patients with a long disease duration (between 7 and 34 years). In addition, we classified the de- and remyelinating activity as described in detail earlier [23]. Actively demyelinating lesion areas (AD) (biopsies: n = 17, autopsies: n = 0) were located at the plaque border, these areas were partially demyelinated and infiltrated by numerous macrophages containing myelin degradation products, such as MBP or CNP within their cytoplasm. Demyelinated lesion areas (DM) were infiltrated by macrophages and T cells, but macrophages did not contain myelin degradation products (biopsies: n = 7, autopsies: n = 11). In remyelinating/remyelinated areas (RM) (biopsies: n = 15, autopsies: n = 6), thin, irregularly formed myelin sheaths were seen. Remyelinating lesions early during disease course were infiltrated by numerous macrophages and T cells while remyelinating plaques from chronic multiple sclerosis are characterized by a very mild inflammatory reaction. Periplaque white matter (PPWM) (biopsies: n = 25, autopsies: n = 8) showed no signs of demyelination.

3. Immunohistochemistry

Tissue specimens were fixed in 4% paraformaldehyde and embedded in paraffin. Tissue samples were cut in 4 µm thick sections that were stained with haematoxylin and eosin and Luxol-fast blue. Immunohistochemical staining was performed with an avidin-biotin technique. After deparaffinization intrinsic peroxidase activity was blocked by incubation with 5% H2O2 in PBS for 20 min. Non-specific antibody binding was inhibited with 10% FCS in PBS for 25 min. The primary antibodies were rabbit anti-TCF7L2 (1:100) (Cell Signaling, Boston, USA), mouse anti-TCF7L2 (1:300) (Abnova), rabbit anti-HDAC2 (1:200) (Santa Cruz Biotechnology, Santa Cruz, USA), rabbit anti-myelin basic protein (1:1000) (Boehringer Mannheim, Mannheim, Germany), mouse anti-KiM1P (1:5000) (H.-J. Radzun, Department of Pathology, University of Göttingen, Germany), mouse anti-CD3 (Dako) (1:25), rabbit anti-GFAP (1:2000) (Dako, Denmark), mouse anti-GFAP (1:50) (Dako, Denmark), rabbit anti-Olig2 (1:300) (IBL, Spring Lake Park, Minnesota), rabbit anti-Nogo-A (1:750) (Chemicon International, Temecula, CA) and mouse anti-Nogo-A (1:15.000) (11c7, a generous gift from M.E. Schwab, Brain Research Institute, University of Zürich and Department of Biology, Swiss Federal Institute of Technology, Zürich, Switzerland). For double stainings, we combined mouse or rabbit anti-NogoA or anti-Olig2 antibodies with anti-TCF7L2 or HDAC2. A combined avidin-biotin/alkaline phospahtase (AP) technique was used, using biotinylated and AP-conjugated secondary antibodies (1:50) (Dako, Glostrup, Denmark). Alternatively, secondary antibodies conjugated either to Cy2 or Cy3 (1:200) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) were used.

4. Human fetal OPC cultures

For all human tissue samples used in the in vitro studies written informed consent was obtained. Human fetal brain tissue obtained from 15- to 17-gestational week embryos was provided by the Human Fetal Tissue Repository (Albert Einstein College of Medicine, Bronx, NY). Both the Albert Einstein College of Medicine and McGill University institutional review boards approved these studies. A2B5 expressing cells were isolated immuno-magnetically as previously described [24,25]. The purified cells were plated on a matrix of lysed human fetal astrocytes grown on poly-L-lysine-coated plastic coverslips (astrocyte matrix) (Nunc, Rochester, NY) as described previously (8,9). The cultures were grown in Dulbecco’s modified essential medium (DMEM)-F12 supplemented with N1 (Sigma, Oakville, ON), 0.01% bovine serum albumin (BSA), 1% penicillin-streptomycin, B27 supplement (Invitrogen, Burlington, ON), Thyroid hormone (T3, 2 ng/ml, Sigma, Oakville, ON), Platelet-derived growth factor AA (PDGF-AA, 10 ng/ml, Sigma, Oakville, ON) and Basic fibroblast growth factor (bFGF, 20 ng/ml, Sigma, Oakville, ON).

5. Immunocytochemistry

For assessment of cell surface markers, cells were stained with monoclonal antibody O4 (1:50, Hybridoma from Dr. Timothy Kennedy) for 30 min at 4°C then fixed with 4% paraformaldehyde for 10 min at 4°C, followed by blocking with HHG (1 mM HEPES, 2% horse serum, 10% goat serum, Hanks’ balanced salt solution) for 10 min. Cultures were incubated with Goat anti-mouse monoclonal IgM-FITC (1:100, Jackson ImmunoResearch, Westgrove, PA) for 30 min at 4°C. Cells were further stained with polyclonal anti-TCF7L2 (1:100, Cell signaling, Boston, USA) antibody for 1 hour followed by polyclonal goat anti rabbit Cy3 secondary antibody (1:250, Jackson ImmunoResearch) 45 min at room temperature. Antibody isotype controls showed low nonspecific staining (data not shown). Cell nuclei were stained with Hoechst 33258 (1:1000, invitrogen) for 10 min at room temperature. Slides were mounted using gel/mount (Biomeda Corporation, Foster City, CA), and stains were visualized using epifluorescent microscopy (Leica, Montreal, QC) and OpenLab imaging software (OpenLab, Florence, Italy).

6. Morphometry and statistics

The numbers of TCF7L2, OLIG2 and NOGOA-positive cells stained with the corresponding antibodies were determined in at least 10 standardized microscopic fields of 10.000 µm2 each defined by an ocular morphometric grid. In the text and figures, the mean number of cells/mm2 ± SEM is given. For statistical analysis, Student t-tests were performed; Bonferroni-corrected one-way or two-way ANOVA tests were performed for multiple comparisons. All tests were classified as significant if the P-value was < 0.05. The GraphPad PRISM™ software was used (Graph Pad Software, Inc., San Diego, CA, USA) for these analyses.

Results

1. TCF7L2 expression during murine CNS myelination and toxic demyelination

CNS myelination.

Myelination was examined using immunohistochemistry for MBP. At P10 myelination was patchy whereas at P21 myelination was almost complete compared to 8 weeks old adult mice (Figure 1A and B). To determine the expression of TCF7L2 during myelination, we quantified the expression of TCF7L2-positive cells in the corpus callosum of P10, P21, or adult mice (8 weeks and 8 months). We observed a decrease of TCF7L2-positive cells over time with significantly higher numbers at P10 (197 +/- 27 cells/mm2) and P21 (226 +/- 25 cells/mm2) compared to 8 weeks (78 9 +/- 17 cells/mm2) or eight months old mice (10 +/- 6 cells/mm2) (Figure 1C–E). The numbers of cells expressing OLIG2, a marker expressed by oligodendroglial lineage cells, increased significantly from P10 to P21 and peaked in adult animals (Figure 1F). Double stainings for TCF7L2 and OLIG2 revealed that almost all TCF7L2-positive cells were OLIG2 positive, only in two out of 13 mice we observed single TCF7L2-positive cell which did not express OLIG2. The number of OLIG2 positive cells expressing also TCF7L2 decreased from approximately 10% at day P10 and P21 to less than 2% at 8 weeks of age (Figure 1G).

thumbnail

Figure 1. Expression of TCF7L2 during myelination in the CNS of mice.

At P10 single myelinated axons are observed in the lateral parts of the corpus callosum (arrow) (A) whereas in adult mice myelination is complete (B). High numbers of TCF7L2 expressing cells were observed in P10 mice (C), but only few TCF7L2-positive cells were found in adult mice (D) as quantified in the diagrams (E and F). The percentage of OLIG2 positive cells expressing TCF7L2 decreased significantly in adult mice (G).

doi:10.1371/journal.pone.0072822.g001
Toxic demyelination.

Feeding of mice with a cuprizone diet (0.25%) led to oligodendroglial cell death and subsequent demyelination. Oligodendroglial cell death started already after four days of cuprizone diet and reached its peak about three weeks after onset of cuprizone diet [26,27]. To identify oligodendroglial lineage cells we used two different markers. Whereas NOGOA expression is restricted to mature oligodendrocytes OLIG2 is detected in all cells of the oligodendroglial lineage [28]. Although maximal demyelination was observed after six weeks of cuprizone, lowest numbers of NOGOA and OLIG2-positive cells were observed 21 days after onset of cuprizone diet with an increase during the following weeks demonstrating the recruitment of oligodendroglial lineage cells already during the cuprizone diet (Figure 2A and B). Significant upregulation of TCF7L2 was most prominent at day 42 after onset of cuprizone induced demyelination indicating that TCF7L2 is only expressed at a certain stage of oligodendroglial differentiation (Figure 2C).

thumbnail

Figure 2. Expression of TCF7L2 during remyelination in the CNS of mice.

Mice were fed with 0.25% cuprizone for six weeks and the numbers of oligodendroglial lineage cells were quantified at the indicated time points. Lowest numbers of OLIG2 positive cells were observed 21 days after onset of cuprizone diet; the increased numbers at the end of the cuprizone diet (at 42 days) suggest a recruitment of OPCs during ongoing demyelination (A). NOGOA is expressed by mature oligodendrocytes; lowest numbers of NOGOA positive cells were as well found at day 21 (B). High numbers of TCF7L2 expressing cells were only detected at day 42 (C).

doi:10.1371/journal.pone.0072822.g002

2. TCF7L2 expression during human CNS myelination

To determine whether TCF7L2 follows a similar time course during human myelination as in mouse CNS we stained cerebellar and frontal lobe tissue specimens from fetuses (gestation week 32 to 40) and newborns and infants (2 to 48 months) for MBP to determine the course of myelination in the human CNS during development. As expected, myelination in the cerebellum preceded myelination of the frontal lobe (data not shown). Whereas the cerebellum showed already significant myelination at gestation week 32, myelination of the frontal lobes started around birth and was completed approximately 8 months after birth (Figure 3A and C). In frontal lobes, first TCF7L2 expression was observed between the 36th and 40th week of gestation, the highest number of cells expressing TCF7L2 was detected between months 7 and 12 after birth (Figure 3B). Afterwards, TCF7L2 expression decreased and no expression was found 48 months after birth. In white matter tissue specimens from adults (aged between 29 and 64) only single TCF7L2 positive cells were found (mean 5 +/-2 cells/mm2; range 0-17/mm2, n =9). Double stainings with NOGOA demonstrated that between 50 and 100% (mean 78 +/-6%) of TCF7L2-positive cells also expressed NOGOA in developmental tissue sampes (3D). Similarly, primary OPCs cultured from fetal human CNS expressed TCF7L2 as well (Figure 3F). To determine whether astrocytes express TCF7L2 we performed the appropriate double stainings. However, no TCF7L2-positive astrocytes were detected in developmental tissue samples (Figure 3E). Together, these data suggest that TCF7L2 expression during CNS myelination is restricted to a defined stage of oligodendroglial differentiation similar to the findings in murine CNS.

thumbnail

Figure 3. Myelination and expression of TCF7L2 in the human CNS.

The extent of myelination in human frontal lobes was quantified using a semiquantitative score. Between 30 and 40 weeks of gestation no MBP-positive axons were found. Myelination became first obvious between 0 and 6 months after birth (A). First TCF7L2-positive cells were detected at the end of gestation with maximal numbers between 7 and 12 months after birth. Afterwards, the numbers of TCF7L2-positive cells decreased quickly (B). At 6 months after birth numerous myelinating oligodendrocytes were observed (immunohistochemistry for MBP) (C). Many TCF7L2 positive cells also expressed NOGOA (double immunohistochemistry for NogoA (red) and TCF7L2 (black) (D) but not GFAP (double immunohistochemistry for TCF7L2 (black) and GFAP (red)) (E). TCF7L2 was also expressed in human fetal oligodendrocytes in vitro (green O4, red TCF7L2) (F).

doi:10.1371/journal.pone.0072822.g003

3. TCF7L2 expression in human demyelinating diseases and other inflammatory non-demyelinating diseases

To further study the role of TCF7L2 expression in demyelinating and inflammatory CNS diseases we analyzed the expression of TCF7L2 in early and chronic MS lesions as well as in inflammatory non demyelinating tissue samples. Early MS lesions were characterized by a homogeneous infiltration of macrophages/microglia (between 1602 +/- 65 cells/mm2 in actively demyelinating and 1234/mm2 in remyelinating lesion areas); T cells were present in lower numbers (between 118 +/- 24 cells/mm2 in remyelinating and 181 +/- 66 cells/mm2 in demyelinated lesion areas) and were located perivascularly or within the parenchyma (Figure 4 A and B). Macrophages/microglia numbers were significantly lower in PPWM than lesions; however no significant differences were observed between actively demyelinating, demyelinated or remyelinated lesion areas in early MS lesions (Figure 4A). The numbers of oligodendrocytes were significantly reduced in all lesion areas compared to PPWM (Figure 4C). We detected TCF7L2-positive cells in 23 out of 33 tissue samples from patients with early MS. In early MS lesions the majority of TCF7L2-positive cells were found in the PPWM (36 +/- 8 cells/mm2) and remyelinating lesion areas (34 +/- 15 cells/mm2) whereas fewer cells were counted in actively demyelinating and demyelinated lesions areas (2.4 +/- 1.2 and 3.9 +/- 2.1 cells/mm2) (Figure 5A). In contrast, in control tissue samples from patients without neurological diseases, only single positive cells were found (mean 5 cells/mm2; range 0-16.7/mm2, n =9) as mentioned above. Double stainings with TCF7L2 and NOGOA, revealed that many TCF7L2 positive cells also expressed NOGOA (mean 34. +/- 11%, range 0-67%) (Figure 5C). However, also single TCF7L2- and GFAP positive cells were detected. When the lesions were stratified with respect to the presence or absence of remyelination within the biopsy specimen no significant differences were observed. Furthermore, no correlation between the numbers of TCF7L2- and NOGOA positive cells was found (Figure 5B). In tissue samples from four MS patients (patient no. 2, 6, 26 and 30, see Table 1) high numbers of TCF7L2 positive cells were detected (PPWM (n=1), actively demyelinating (n = 1) or remyelinating (n = 2) lesion areas) (Figure 5A); however no obvious differences with respect to numbers of T cells, macrophages or NOGOA positive oligodendrocytes were found (Figure 4A to C).

thumbnail

Figure 4. Quantification of macrophages/microglia, T cells, and oligodendrocytes in inflammatory demyelinating and non-demyelinating human CNS diseases.

Tissue samples from patients with early MS and non-demyelinating inflammatory diseases were stained for macrophages/microglia (anti-KiM1P), T cells (anti-CD3) and oligodendrocytes (anti-NOGOA). Numbers of macrophages/microglia were significantly increased in all lesion areas compared to PPWM (A). T cells were highest in patients with inflammatory, non-demyelinating CNS diseases (B). Oligodendrocytes were significantly decreased in all MS lesion areas (C). The red dots (A to C) indicate tissue samples with high numbers of TCF7L2 expressing cells (see Figure 5); however no obvious difference between these tissue samples and the others were observed with respect to macrophages, T cells and oligodendrocytes.

PPWM = periplaque white matter, AD = actively demyelinating, DM = demyelinated, RM = remyelinating/remyelinated, OND = other inflammatory neurological diseases.

doi:10.1371/journal.pone.0072822.g004
thumbnail

Figure 5. Expression of TCF7L2 in MS lesions and non-demyelinating inflammatory CNS diseases.

In a subset of early MS lesions increased numbers of TCF7L2 positive cells were detected in the periplaque white matter and in remyelinating lesion areas. However, also in other inflammatory neurological diseases (OND) TCF7L2 positive cells were present. Red dots indicate a subset of tissue samples with high numbers of TCF7L2 expressing cells (see Figure 4) (A). There was no correlation between numbers of TCF7L2 and NOGOA positive cells in the different MS lesion areas. NOGOA positive oligodendrocytes and TCF7L2 expressing cells were quantified in periplaque white matter (PPWM), actively demyelinating (AD), demyelinated (DM) and remyelinating (RM) lesion areas; TCF7L2 expressing cells (dots) and NOGOA expressing cells (squares) from the same lesion area are labelled in the same colour (B). Double stainings revealed that a subset of TCF7L2 positive cells were NOGOA positive oligodendrocytes (arrows). TCF7L2 negative oligodendrocytes are indicated by arrow heads (Double immunohistochemistry for NOGOA (red) and TCF7L2 (black) (C). In inflammatory non demyelinating disease TCF7L2 positive oligodendrocytes and astrocytes were detected (D and E). In D a GFAP and TCF7L2 positive astrocyte (arrow) as well as a GFAP negative TCF7L2 positive cell (arrow head) are depicted (double immunohistochemistry for GFAP (green) and TCF7L2 (red). Additional GFAP and TCF7L2 positive cells are shown in E (arrows) (double immunohistochemistry for GFAP (red) and TCF7L2 (black)).

doi:10.1371/journal.pone.0072822.g005

In chronic MS lesions (18 lesions from 12 patients) in which inflammation was limited to the lesion border (chronic active) or was almost completely absent (chronic inactive) no TCF7L2 expression was found (Figure 5A).

To determine whether the reexpression of TCF7L2 is restricted to demyelinating diseases such as MS, we stained ten tissue samples from eight patients with inflammatory but non demyelinating diseases (e.g. encephalitis, vasculitis). Macrophages/microglia numbers were significantly lower whereas T cell numbers were significantly higher in tissue samples from patients with non-demyelinating neurological diseases compared to patients with early MS lesions (Figure 4A and B). As expected, oligodendrocytes were not reduced in this set of tissue samples (Figure 4C). TCF7L2 positive cells were found in comparable numbers as in the periplaque white matter of early MS lesions (Figure 5A). Many TCF7L2 positive cells expressed NOGOA (mean 25. +/-12%, range 0-100%); additionally many TCF7L2 and GFAP double positive cells were detected (mean 34 +/-14%, range 0-100%) demonstrating that the expression of TCF7L2 is not restricted to the oligodendroglial lineage in inflammatory conditions (Figure 4C and D). In one tissue sample (patient no 53, Table 1) high numbers of TCF7L2-positive cells were observed, again no obvious difference in the extent or composition of the inflammatory infiltrate was observed (Figure 4A and B).

In summary, these data demonstrate that TCF7L2 is expressed in early but not chronic MS lesions. However, the TCF7L2 expression is not limited to demyelinating conditions or the oligodendroglial lineage.

4. Expression of HDAC2 in early MS lesions and healthy controls

Recent publications suggest that binding of TCF7L2 to β-catenin or HDAC1/2 either inhibits or promotes the differentiation of oligodendroglial lineage cells [19]. The presence and upregulation of β-catenin or other components of the wnt/β-catenin pathway in MS lesions have been described in earlier publications [29,30]. Therefore, we analyzed the expression of HDAC2 in a subset of MS lesions and in tissue samples from healthy controls. In control samples as well as in MS lesions numerous HDAC2-positive cells were observed by immunohistochemistry (Figure 6A and B). In MS tissue samples between 78 and 100% (mean 96 +/- 6%) of NOGOA expressing oligodendrocytes expressed also HDAC2 comparable to tissue samples from healthy controls (mean 94 +/- 6; range 83-100%).

thumbnail

Figure 6. Expression of HDAC2 in MS lesions and control tissue samples.

In control tissue samples (A) as well as in MS lesions (B) numerous NOGOA positive oligodendrocytes were seen which express abundantly HDAC2 (arrows) (double immunohistochemistry for NOGOA (red) and HDAC2 (black)).

doi:10.1371/journal.pone.0072822.g006

In summary, these data indicate that HDAC2 is abundantly expressed in the nucleus of oligodendrocytes in early MS lesions.

Discussion

Here, we demonstrate that the transcription factor TCF7L2 is expressed during development and downregulated in adulthood in oligodendroglial lineage cells. Furthermore, in demyelinating and inflammatory diseases TCF7L2 is reexpressed, but the expression of TCF7L2 is not restricted to oligodendrocytes. Furthermore, the potential TCF7L2 binding partner HDAC2 is abundantly expressed in oligodendroglial lineage cells.

TCF7L2 belongs to a subfamily of high mobility group (HMG)-box-containing superfamily of transcription factors. TCF7L2 binds to the Wnt response element; however for regulating transcription TCF7L2 requires additional cofactors (for review, see 31). Without β-catenin TCF7L2 acts as a transcriptional repressor, e.g. by binding Groucho/TLE (reviewed by [32]). Deficiency of TCF7L2 is associated with impaired oligodendroglial differentiation [19]. Misexpression of a dominant repressive TCF7L2 mutant that lacks the β-catenin binding site promotes ectopic expression of early oligodendroglial markers suggesting that a TCF7L2 mediated, β-catenin independent repressor interaction drives oligodendrocyte precursor formation [19]. During developmental myelination, we observed a temporally regulated expression of TCF7L2 in human and murine white matter which was limited to oligodendroglial lineage cells expressing OLIG2. This observation is in line with an earlier publication [18]. During myelination, many TCF7L2 positive cells express also NOGOA, a marker of mature oligodendrocytes that does not colocalizes with NG2 [28]. The presence of TCF7L2 positive cells that do not express NOGOA suggests that TCF7L2 is expressed in oligodendroglial lineage cells at the transition from immature to mature oligodendrocytes. This hypothesis is corroborated by the finding that TCF7L2 expression in the human and murine CNS peaks approximately at the same time point as myelination. During cuprizone induced de- and remyelination maximal TCF7L2 expression was observed at day 42 after onset of cuprizone feeding, a time point at which remyelination is initiated. In contrast, the recruitment of progenitors starts already during the cuprizone diet as indicated by the increase of OLIG2 or NOGOA positive oligodendroglial cells during late stages of cuprizone induced demyelination and as described by Matsushima and colleagues [27]. These findings suggest that TCF7L2 is upregulated during a defined differentiation stage of oligodendroglial lineage cells at the transition from OPCs to mature oligodendrocytes.

In human demyelinating diseases the situation is more complex. Earlier studies reported the expression of TCF7L2 in inflammatory MS lesions [18]. This finding together with the developmental observations suggested that expression of TCF7L2 might be used to identify differentiating or remyelinating oligodendrocytes; this hypothesis was supported by our finding that relatively high numbers of TCF7L2-positive cells were observed in a subset of remyelinating but not in actively demyelinating, demyelinated or chronic MS lesions. However, we observed TCF7L2 positive cells only in 8 out of 15 lesion areas with remyelination; this might be explained by the fact that expression of TCF7L2 is restricted to a narrow time window during oligodendroglial differentiation. The presence of TCF7L2 positive oligodendrocytes in tissue samples from patients with an inflammatory but not demyelinating disease may suggests that also in these inflammatory conditions OPCs differentiate into oligodendrocytes due to an inflammation induced oligodendroglial turnover as it has been reported for experimental models of injury [33] (for review, see 34). Surprisingly, we found also expression of TCF7L2 in astrocytes in human demyelinating and inflammatory disease that appeared weaker than in oligodendrocytes. The biological significance of this finding is unclear; since so far little is known about the functional role of TCF7L2 in astrocytes [35].

TCF7L2 is a well-known co-activator of β-catenin and activation of the canonical wnt/β-catenin pathway in vitro or in vivo impairs oligodendroglial differentiation [18,19,3638]. The presence of members of the wnt/β-catenin pathway in MS lesions as well as recent observations that enforced constitutive expression of β-catenin inhibited myelination and differentiation of oligodendrocytes led to the suggestion that a disturbed wnt/β-catenin-pathway may contribute to remyelination failure in chronic MS lesions [18,19,30,39]. Furthermore, in animal studies prevention of the translocation of β-catenin to the nucleus promotes remyelination and myelination [29]. Without β-catenin TCF/LEFs assemble alternative complexes with other transcriptional co-repressors, such as Groucho/TLE or Smad3 [32,40]. Recent findings suggest that HDAC1 and 2 may compete with β-catenin for the binding to TCF7L2 thereby antagonizing the effect of wnt signaling and promoting oligodendroglial differentiation [19]. In our tissue samples we found a strong expression of HDAC2 in oligodendrocytes during CNS myelination, in healthy controls and in MS lesions. Therefore, it cannot be excluded that TCF7L2 binds to HDACs in oligodendrocytes resulting in the differentiation of oligodendrocytes, expression of myelin genes and initiation of remyelination at least in a subset of MS lesions.

In summary, we have shown that TCF7L2 is expressed during development and early MS lesion stages in oligodendrocytes. However, the expression of TCF7L2 is neither limited to oligodendrocytes nor to demyelinating conditions. Further studies are required to dissect further the functional role of TCF7L2 in oligodendrocytes and astrocytes during remyelination and myelination.

Author Contributions

Conceived and designed the experiments: TK WB JA. Performed the experiments: AL KH QC. Analyzed the data: AL QC TK. Contributed reagents/materials/analysis tools: WB IM JA TK. Wrote the manuscript: AL TK.

References

  1. 1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285. doi:10.1056/NEJM199801293380502. PubMed: 9445407.
  2. 2. Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12: 295-302. doi:10.1097/00019052-199906000-00008. PubMed: 10499174.
  3. 3. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120: 393-399. doi:10.1093/brain/120.3.393. PubMed: 9126051.
  4. 4. Schirmer L, Antel JP, Brück W, Stadelmann C (2011) Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis. Brain Pathol 21: 428-440. doi:10.1111/j.1750-3639.2010.00466.x. PubMed: 21114565.
  5. 5. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J et al. (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121: 1469-1477. doi:10.1093/brain/121.8.1469. PubMed: 9712009.
  6. 6. Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH et al. (2010) Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 16: 406-411. doi:10.1177/1352458510364992. PubMed: 20215480.
  7. 7. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J et al. (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33: 366-374. doi:10.1038/ng1095. PubMed: 12590258.
  8. 8. Neumann H (2003) Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr Opin Neurol 16: 267-273. doi:10.1097/00019052-200306000-00004. PubMed: 12858061.
  9. 9. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis. A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157: 267-276. doi:10.1016/S0002-9440(10)64537-3. PubMed: 10880396.
  10. 10. Irvine KA, Blakemore WF (2008) Remyelination protects axons from demyelination-associated axon degeneration. Brain 131: 1464-1477. doi:10.1093/brain/awn080. PubMed: 18490361.
  11. 11. Duncan ID, Brower A, Kondo Y, Curlee JF Jr., Schultz RD (2009) Extensive remyelination of the CNS leads to functional recovery. Proc Natl Acad Sci U S A 106: 6832-6836. doi:10.1073/pnas.0812500106. PubMed: 19342494.
  12. 12. Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T (2009) Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72: 1914-1921. doi:10.1212/WNL.0b013e3181a8260a. PubMed: 19487649.
  13. 13. Patani R, Balaratnam M, Vora A, Reynolds R (2007) Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 33: 277-287. doi:10.1111/j.1365-2990.2007.00805.x. PubMed: 17442065.
  14. 14. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M et al. (2006) Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129: 3165-3172. doi:10.1093/brain/awl217. PubMed: 16921173.
  15. 15. Chang A, Tourtellotte WW, Rudick R, Trapp BD (2002) Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346: 165-173. doi:10.1056/NEJMoa010994. PubMed: 11796850.
  16. 16. Wolswijk G (1998) Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis. Prog Brain Res 117: 233-247. doi:10.1016/S0079-6123(08)64019-4. PubMed: 9932412.
  17. 17. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J et al. (2008) Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131: 1749-1758. doi:10.1093/brain/awn096. PubMed: 18515322.
  18. 18. Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA et al. (2009) Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 23: 1571-1585. doi:10.1101/gad.1806309. PubMed: 19515974.
  19. 19. Ye F, Chen Y, Hoang T, Montgomery RL, Zhao XH et al. (2009) HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci 12: 829-838. doi:10.1038/nn.2333. PubMed: 19503085.
  20. 20. Prineas JW (1985) The neuropathology of multiple sclerosis. In: Koetsier JC. Demyelinating Diseases. Amsterdam: Elsevier Science Publishers. pp. 213-257.
  21. 21. Allen IV (1991) Pathology of multiple sclerosis. In: Matthews WB. McAlpine’s Multiple Sclerosis. Edinburgh: Churchill Livingstone. pp. 341-378.
  22. 22. Lassmann H (1998) Pathology of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, McDonald I, Matthews B et al. McAlpine`s Multiple Sclerosis. . London: Churchill Livingstone . pp. 323-358.
  23. 23. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F et al. (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38: 788-796. doi:10.1002/ana.410380514. PubMed: 7486871.
  24. 24. Ruffini F, Arbour N, Blain M, Olivier A, Antel JP (2004) Distinctive properties of human adult brain-derived myelin progenitor cells. Am J Pathol 165: 2167-2175. doi:10.1016/S0002-9440(10)63266-X. PubMed: 15579458.
  25. 25. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B et al. (2008) FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 63: 61-71. doi:10.1002/ana.21227. PubMed: 17918267.
  26. 26. Hesse A, Wagner M, Held J, Brück W, Salinas-Riester G et al. (2010) In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. Neurobiol Dis 37: 362-369. doi:10.1016/j.nbd.2009.10.016. PubMed: 19853662.
  27. 27. Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11: 107-116. PubMed: 11145196.
  28. 28. Kuhlmann T, Remington L, Maruschak B, Owens T, Brück W (2007) Nogo-A is a reliable oligodendroglial marker in adult human and mouse CNS and in demyelinated lesions. J Neuropathol Exp Neurol 66: 238-246. doi:10.1097/01.jnen.0000248559.83573.71. PubMed: 17356385.
  29. 29. Fancy SP, Harrington EP, Yuen TJ, Silbereis JC, Zhao C et al. (2011) Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci 14: 1009-1016. doi:10.1038/nn.2855. PubMed: 21706018.
  30. 30. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV et al. (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451: 1076-1081. doi:10.1038/nature06559. PubMed: 18278032.
  31. 31. Hoppler S, Kavanagh CL (2007) Wnt signalling: variety at the core. J Cell Sci 120: 385-393. doi:10.1242/jcs.03363. PubMed: 17251379.
  32. 32. Daniels DL, Weis WI (2005) Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 12: 364-371. doi:10.1038/nsmb912. PubMed: 15768032.
  33. 33. Yang H, Lu P, McKay HM, Bernot T, Keirstead H et al. (2006) Endogenous neurogenesis replaces oligodendrocytes and astrocytes after primate spinal cord injury. J Neurosci 26: 2157-2166. doi:10.1523/JNEUROSCI.4070-05.2005. PubMed: 16495442.
  34. 34. McTigue DM, Tripathi RB (2008) The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 107: 1-19. doi:10.1111/j.1471-4159.2008.05570.x. PubMed: 18643793.
  35. 35. Carroll-Anzinger D, Kumar A, Adarichev V, Kashanchi F, Al-Harthi L (2007) Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway. J Virol 81: 5864-5871. doi:10.1128/JVI.02234-06. PubMed: 17392368.
  36. 36. Kim S, Kim SH, Kim H, Chung AY, Cha YI et al. (2008) Frizzled 8a function is required for oligodendrocyte development in the zebrafish spinal cord. Dev Dyn 237: 3324-3331. doi:10.1002/dvdy.21739. PubMed: 18924237.
  37. 37. Feigenson K, Reid M, See J, Crenshaw EB III, Grinspan JB (2009) Wnt signaling is sufficient to perturb oligodendrocyte maturation. Mol Cell Neurosci 42: 255-265. doi:10.1016/j.mcn.2009.07.010. PubMed: 19619658.
  38. 38. Azim K, Butt AM (2011) GSK3beta negatively regulates oligodendrocyte differentiation and myelination in vivo. Glia 59: 540-553. doi:10.1002/glia.21122. PubMed: 21319221.
  39. 39. Lock CB, Heller RA (2003) Gene microarray analysis of multiple sclerosis lesions. Trends Mol Med 9: 535-541. doi:10.1016/j.molmed.2003.10.008. PubMed: 14659468.
  40. 40. Labbé E, Letamendia A, Attisano L (2000) Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci U S A 97: 8358-8363. doi:10.1073/pnas.150152697. PubMed: 10890911.